Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, versus placebo in scalp, nail, and palmoplantar psoriasis: subset analyses of the phase 3 POETYK PSO-1 and PSO-2 trials. J of Skin [Internet]. 2022 Jul. 7 [cited 2026 Apr. 17];6(4):s41. Available from: https://skin.dermsquared.com/skin/article/view/1666